Опыт медикаментозного прерывания беременности у пациенток со злокачественными заболеваниями
Опыт медикаментозного прерывания беременности у пациенток со злокачественными заболеваниями
Доброхотова Ю.Э., Аракелов С.Э., Данелян С.Ж. и др. Опыт медикаментозного прерывания беременности у пациенток со злокачественными заболеваниями. Гинекология. 2017; 19 (2): 75–78.
________________________________________________
Dobrokhotova Yu.E., Arakelov S.E., Danelian S.Zh. et al. Medical termination of pregnancy in patients with malignant diseases. Gynecology. 2017; 19 (2): 75–78.
Опыт медикаментозного прерывания беременности у пациенток со злокачественными заболеваниями
Доброхотова Ю.Э., Аракелов С.Э., Данелян С.Ж. и др. Опыт медикаментозного прерывания беременности у пациенток со злокачественными заболеваниями. Гинекология. 2017; 19 (2): 75–78.
________________________________________________
Dobrokhotova Yu.E., Arakelov S.E., Danelian S.Zh. et al. Medical termination of pregnancy in patients with malignant diseases. Gynecology. 2017; 19 (2): 75–78.
Распространенность и частота выявления опухолей, ассоциированных с беременностью, неуклонно растет. Выявление злокачественного новообразования всегда ставит врача перед необходимостью принятия решения о возможности и целесообразности сохранения беременности. Определяющим моментом являются характер и стадия патологического процесса и срок беременности. Согласно приказу Министерства здравоохранения и социального развития РФ от 3 декабря 2007 г. №736 «Об утверждении перечня медицинских показаний для искусственного прерывания беременности», в случае выявления новообразования, требующего проведения химиотерапии или лучевой терапии на область малого таза при коде заболевания С51–С58, показано прерывание беременности. Во всех других случаях вопрос о прерывании беременности решается индивидуально консилиумом врачей. В статье представлены кинические случаи медикаментозного прерывания беременности у пациенток со сроком гестации до 20 нед. Ключевые слова: рак, беременность, опухоль, ассоциированная с беременностью, артифициальный аборт, мифепристон, мизопростол.
________________________________________________
The prevalence and detection rate of tumors associated with pregnancy, is growing steadily. Detection of malignant neoplasms has always put the doctor before the need for a decision about the possibility and desirability of pregnancy. The fundamental issue is the nature and stage of pathologic process and duration of pregnancy. According to the Ministry of health and social development of the Russian Federation from December 3, 2007 N736 "On approval of the list of medical indications for artificial interruption of pregnancy", in the case of neoplasms that require chemotherapy or radiotherapy to the pelvic area when the code of the disease С51–58, shows the termination of pregnancy. In all other cases, the question of abortion is solved individually by the doctors. The article presents clinical cases of medical termination of pregnancy in patients with gestational age up to 20 weeks. Key words: cancer, pregnancy, tumor associated with pregnancy, artificial abortion, mifepristone, misoprostol.
1. www.cancer.gov/cancertopics/factsheet/risk/brca
2. www.bt.cdc.gov/radiation/prenatalphysician.asp
3. Stensheim H, Moller B, van Dijk T, Fossa SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 2009; 27: 45.
4. Vercellino GF, Koehler C, Erdemoglu E. Laparoscopic pelvic lymphadenectomy in 32 pregnant patients with cervical cancer: rationale, description of the technique, and outcome. Int J Gynecol Cancer 2014; 24: 364.
5. Amant F, von Minckwitz G, Han SN. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol 2013; 31: 2532.
6. Azim HA Jr, Santoro L, Russell-Edu W. Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. Cancer Treat Rev 2012; 38: 834.
7. Azim HA, Bellettini G, Liptrott SJ. Breastfeeding in breast cancer survivors: pattern, behavior and effect on breast cancer outcome. Ann Oncol 2010; 21 (Suppl. 8): viii89.
8. Leiserowitz GS, Xing G, Cress R. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2006; 101: 315.
9. Palmer J, Vatish M, Tidy J. Epithelial ovarian cancer in pregnancy: a review of the literature. BJOG 2009; 116: 480.
10. Dede M, Yenen MC, Yilmaz A. Treatment of incidental adnexal masses at cesarean section: a retrospective study. Int J Gynecol Cancer 2007; 17: 339.
11. Goff BA, Mandel LS, Drescher CW. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109: 221.
12. Yen CF, Lin SL, Murk W. Risk analysis of torsion and malignancy for adnexal masses during pregnancy. Fertil Steril 2009; 91: 1895.
13. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 2007; 44: 151.
14. Giuntoli RL 2nd, Vang RS, Bristow RE. Evaluation and management of adnexal masses during pregnancy. Clin Obstet Gynecol 2006; 49: 492.
15. Yakasai IA, Bappa LA. Diagnosis and management of adnexal masses in pregnancy. J Surg Tech Case Rep 2012; 4: 79.
16. ACOG Committee on Obstetric Practice. ACOG Committee Opinion. Number 299, September 2004 (replaces No. 158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol 2004; 104: 647.
________________________________________________
1. www.cancer.gov/cancertopics/factsheet/risk/brca
2. www.bt.cdc.gov/radiation/prenatalphysician.asp
3. Stensheim H, Moller B, van Dijk T, Fossa SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 2009; 27: 45.
4. Vercellino GF, Koehler C, Erdemoglu E. Laparoscopic pelvic lymphadenectomy in 32 pregnant patients with cervical cancer: rationale, description of the technique, and outcome. Int J Gynecol Cancer 2014; 24: 364.
5. Amant F, von Minckwitz G, Han SN. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol 2013; 31: 2532.
6. Azim HA Jr, Santoro L, Russell-Edu W. Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. Cancer Treat Rev 2012; 38: 834.
7. Azim HA, Bellettini G, Liptrott SJ. Breastfeeding in breast cancer survivors: pattern, behavior and effect on breast cancer outcome. Ann Oncol 2010; 21 (Suppl. 8): viii89.
8. Leiserowitz GS, Xing G, Cress R. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2006; 101: 315.
9. Palmer J, Vatish M, Tidy J. Epithelial ovarian cancer in pregnancy: a review of the literature. BJOG 2009; 116: 480.
10. Dede M, Yenen MC, Yilmaz A. Treatment of incidental adnexal masses at cesarean section: a retrospective study. Int J Gynecol Cancer 2007; 17: 339.
11. Goff BA, Mandel LS, Drescher CW. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109: 221.
12. Yen CF, Lin SL, Murk W. Risk analysis of torsion and malignancy for adnexal masses during pregnancy. Fertil Steril 2009; 91: 1895.
13. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 2007; 44: 151.
14. Giuntoli RL 2nd, Vang RS, Bristow RE. Evaluation and management of adnexal masses during pregnancy. Clin Obstet Gynecol 2006; 49: 492.
15. Yakasai IA, Bappa LA. Diagnosis and management of adnexal masses in pregnancy. J Surg Tech Case Rep 2012; 4: 79.
16. ACOG Committee on Obstetric Practice. ACOG Committee Opinion. Number 299, September 2004 (replaces No. 158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol 2004; 104: 647.
1. ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
2. ГБУЗ «Городская клиническая больница №40» Департамента здравоохранения г. Москвы. 129301, Россия, Москва, ул. Касаткина, д. 7
*katyanikitina@mail.ru
1. N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
2. City Clinical Hospital №40 of the Department of Health of Moscow. 129301, Russian Federation, Moscow, ul. Kasatkina, d. 7
*katyanikitina@mail.ru